Compass Pathways (CMPS): What Will Come Out of FDA Review Meeting for Depression Drug Candidate COMP360?

Compass Pathways PLC (NASDAQ:CMPS) is among the best psychedelic stocks to buy in 2026. Its flagship psychedelic drug candidate COMP360 is aimed at treating patients with depression. COMP360 uses a type of psychedelic substance called psilocybin, and it’s in the final stages of studies.

Compass Pathways PLC (CMPS): What Will Come Out of FDA Review Meeting for Depression Drug Candidate COMP360?

Pressmaster/Shutterstock.com

On March 3, Compass Pathways PLC (NASDAQ:CMPS) representatives attended TD Cowen’s 46th Annual Healthcare Conference in Boston, MA. They used the conference to highlight promising results from a pair of Phase 3 trials of COMP360, drilling down into the data to explain how the studies met primary endpoints in efficacy and safety.

The FDA granted COMP360 a breakthrough therapy designation. This accelerates filing timelines by 12 to 15 months. Compass Pathways has requested a review meeting with the FDA regarding COMP360 study data. In February, the company said it expected to complete an NDA submission for COMP360 in Q4 2026.

Compass Pathways is initially targeting the treatment-resistant depression market with COMP360. But the company is also exploring the compound as a therapy for post-traumatic stress disorder (PTSD).

Compass Pathways PLC (NASDAQ:CMPS) is a biotechnology company headquartered in London, UK. The company is focused on developing psychedelic treatments for mental health issues. Its flagship drug candidate COMP360 is being developed as a solution for treatment-resistant depression as well as post-traumatic stress disorder.

While we acknowledge the risk and potential of CMPS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.